Advances in catheter technology, gene identification, and cell biology may provide novel treatment options for patients with peripheral arterial disease (PAD) who are not candidates for standard revascularization procedures. Animal studies and recent results in human beings suggest that transfer of growth factors or regulatory genes and transplantation of progenitor cells may provide novel therapy options by inducing therapeutic angiogenesis or by inhibiting restenosis. This review will discuss the development of a variety of catheters for localized endovascular delivery, as well as the various cellular and genetic strategies that exist to restore blood flow to ischemic tissue and to reduce neointimal hyperplasia.
MorishitaR. Recent progress in gene therapy for cardiovascular disease. Circ J.2002;66:1077–1086.
3.
DowellJDRubartMPasumarthiKB. Myocyte and myogenic stem cell transplantation in the heart. Cardiovasc Res.2003;58:336–350.
4.
KuliszewskiMAKutrykMJSandhuR. DNA integrity and transgene expression after passage through the NOGA needle catheter used for therapeutic myocardial angiogenesis. Int J Cardiovasc Intervent. 2000;3:167–172.
5.
OronUHalevyOYaakobiT. Technical delivery of myogenic cells through an endocardial injection catheter for myocardial cell implantation. Int J Cardiovasc Intervent. 2000;3:227–230.
6.
ChazaudBHittingerLSonnetC. Endoventricular porcine autologous myoblast transplantation can be successfully achieved with minor mechanical cell damage. Cardiovasc Res.2003;58:444–450.
7.
MarshallDJPalasisMLeporeJJ. Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer. Mol Ther.2000;1:423–429.
8.
AbruzzoTCloftHJShengelaiaGG. In vitro effects of transcatheter injection on structure, cell viability, and cell metabolism in fibroblast-impregnated alginate microspheres. Radiology. 2001;220:428–435.
9.
FramDBAretzTAzrinMA. Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J Am Coll Cardiol. 1994;23:1570–1577.
10.
PalasisMLuoZBarryJJ. Analysis of adenoviral transport mechanisms in the vessel wall and optimization of gene transfer using local delivery catheters. Hum Gene Ther.2000;11:237–246.
11.
SriramVPattersonC. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery. Circulation. 2001;103:2414–2419.
12.
WillardJELandauCGlamannDB. Genetic modification of the vessel wall. Comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation. 1994;89:2190–2197.
13.
OberhoffMHerdegCAl GhobainyR. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv. 2001;53:562–568.
14.
HongMKWongSCFarbA. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coron Artery Dis.1993;4:1023–1027.
15.
LambertCRLeoneJERowlandSM. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis.1993;4:469–475.
16.
RiessenRRahimizadehHBlessingE. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther.1993;4:749–758.
17.
BaumbachAOberhoffMBohnetA. Efficacy of low-molecular-weight heparin delivery with the Dispatch catheter following balloon angioplasty in the rabbit iliac artery. Cathet Cardiovasc Diagn. 1997;41:303–307.
18.
TahlilOBramiMFeldmanLJ. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res.1997;33:181–187.
19.
PanyamJLofJO'LearyE. Efficiency of Dispatch and Infiltrator cardiac infusion catheters in arterial localization of nanoparticles in a porcine coronary model of restenosis. J Drug Target. 2002;10:515–523.
20.
BarathPPopovADillehayGL. Infiltrator angioplasty balloon catheter: a device for combined angioplasty and intramural site-specific treatment. Cathet Cardiovasc Diagn. 1997;41:333–341.
21.
MitchelJFFramDBGillamLD. Enhanced local intracoronary delivery of heparin with the infiltrator feminine catheter: a comparative study. J Invasive Cardiol. 1999;11:463–470.
22.
DevVEiglerNFishbeinMC. Sustained local drug delivery to the arterial wall via biodegradable microspheres. Cathet Cardiovasc Diagn. 1997;41:324–332.
23.
Gottsauner-WolfMJangYPennMS. Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. Cathet Cardiovasc Diagn. 1997;42:102–108.
24.
OberhoffMHerdegCBaumbachA. Time course of smooth muscle cell proliferation after local drug delivery of low-molecular-weight heparin using a porous balloon catheter. Cathet Cardiovasc Diagn. 1997;41:268–274.
25.
OberhoffMKunertWHerdegC. Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. Basic Res Cardiol. 2001;96:275–282.
26.
HerdegCOberhoffMBaumbachA. Local drug delivery with porous balloons in the rabbit: assessment of vascular injury for an improvement of application parameters. Cathet Cardiovasc Diagn. 1997;41:308–314.
27.
Fernandez-OrtizAMeyerBJMailhacA. A new approach for local intravascular drug delivery: iontophoretic balloon. Circulation. 1994;89:1518–1522.
28.
MitchelJFAzrinMAFramDB. Localized delivery of heparin to angioplasty sites with iontophoresis. Cathet Cardiovasc Diagn. 1997;41:315–323.
29.
RobinsonKAChronosNASchiefferE. Pharmacokinetics and tissue localization of antisense oligonucleotides in balloon-injured pig coronary arteries after local delivery with an iontophoretic balloon catheter. Cathet Cardiovasc Diagn. 1997;41:354–359.
30.
RisauWFlammeI. Vasculogenesis. Annu Rev Cell Dev Biol.1995;11:73–91.
TakeshitaSZhengLPBrogiE. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93:662–670.
33.
RissanenTTVajantoIYla-HerttualaS. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb—on the way to the clinic. Eur J Clin Invest. 2001;31:651–666.
KusumantoYHHospersGAMulderNH. Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review. Int J Cardiovasc Intervent. 2003;5:27–34.
36.
FerraraNHenzelWJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–858.
37.
BaffourRBermanJGarbJL. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg.1992;16:181–191.
38.
ChlebounJOMartinsRN. The development and enhancement of the collateral circulation in an animal model of lower limb ischaemia. Aust N Z J Surg.1994;64:202–207.
39.
TakeshitaSPuLQSteinLA. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 1994;90:II228–234.
40.
IsnerJMPieczekASchainfeldR. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996;348:370–374.
41.
BaumgartnerIPieczekAManorO. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114–1123.
42.
RajagopalanSShahMLucianoA. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation. 2001;104:753–755.
43.
RajagopalanSMohlerELedermanRJ. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J.2003;145:1114–1118.
44.
RajagopalanSMohlerERLedermanRJ. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–1938.
45.
MakinenKManninenHHedmanM. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther.2002;6:127–133.
46.
LazarousDFUngerEFEpsteinSE. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol. 2000;36:1239–1244.
47.
GrinesCLWatkinsMWMahmarianJJ. A randomized, double-blind, placebo-controlled trial of Ad5FGF–4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42:1339–1347.
48.
ProckopDJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–74.
49.
AsaharaTMuroharaTSullivanA. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967.
50.
KalkaCTehraniHLaudenbergB. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg.2000;70:829–834.
51.
KoizumiKTsutsumiYKamadaH. Incorporation of adult organ-derived endothelial cells into tumor blood vessel. Biochem Biophys Res Commun. 2003;306:219–224.
52.
Planat-BenardVSilvestreJSCousinB. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 2004;109:656–663.
53.
KoikeNFukumuraDGrallaO. Tissue engineering: creation of long-lasting blood vessels. Nature. 2004;428:138–139.
54.
IshiiSKoyamaHMiyataT. Appropriate control of ex vivo gene therapy delivering basic fibroblast growth factor promotes successful and safe development of collateral vessels in rabbit model of hind limb ischemia. J Vasc Surg.2004;39:629–638.
55.
HamanoKLiTSKobayashiT. Therapeutic angiogenesis induced by local autologous bone marrow cell implantation. Ann Thorac Surg.2002;73:1210–1215.
56.
FuchsSBaffourRZhouYF. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37:1726–1732.
57.
Tateishi-YuyamaEMatsubaraHMuroharaT. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–435.
58.
EsatoKHamanoKLiTS. Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant. 2002;11:747–752.
59.
BautersCIsnerJM. The biology of restenosis. Prog Cardiovasc Dis.1997;40:107–116.
60.
HiltunenMONiemiMYla-HerttualaS. Functional genomics and DNA array techniques in atherosclerosis research. Curr Opin Lipidol. 1999;10:515–519.
61.
FaberBCCleutjensKBNiessenRL. Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res.2001;89:547–554.
62.
HiltunenMOTuomistoTTNiemiM. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis. 2002;165:23–32.
63.
WoodsideKJHernandezASmithFW. Differential gene expression in primary and recurrent carotid stenosis. Biochem Biophys Res Commun. 2003;302:509–514.
64.
KotaniMFukudaNAndoH. Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Cardiovasc Res.2003;57:265–276.
65.
ZohlnhoferDKleinCARichterT. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein 12 upregulation. Circulation. 2001;103:1396–1402.
66.
ArmstrongPJJohanningJMCaltonWC. Differential gene expression in human abdominal aorta: aneurysmal versus occlusive disease. J Vasc Surg.2002;35:346–355.
67.
ChangMWBarrESeltzerJ. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518–522.
68.
ChangMWBarrELuMM. Adenovirus-mediated over-expression of the cyclin/cyclindependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260–2268.
69.
StabileEZhouYFSajiM. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ Res.2003;93:1059–1065.
70.
MaillardLVan BelleESmithRC. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res.1997;35:536–546.
71.
HarrellRLRajanayagamSDoanesAM. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 1997;96:621–627.
72.
GuzmanRJHirschowitzEABrodySL. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA. 1994;91:10732–10736.
73.
OhtaniKEgashiraKUsuiM. Inhibition of neointimal hyperplasia after balloon injury by cis-element ‘decoy’ of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther.2004;11:126–32.
74.
YamasakiKAsaiTShimizuM. Inhibition of NFkappaB activation using cis-element ‘decoy’ of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther.2003;10:356–64.
75.
AutieriMVYueTLFersteinGZ. Antisense oligonucleotides to the p65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun. 1995;213:827–836.
KingstonPASinhaSApplebyCE. Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation. 2003;108:2819–2825.
78.
UsuiMEgashiraKOhtaniK. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J.2002;16:1838–1840.
79.
StumpMMJordanGLDeBakeyME. Endothelium grown from circulating blood on isolated intravascular Dacron hub. Am J Pathol. 1963;43:361–367.
80.
KennedyLJWeissmanIL. Dual origin of intimal cells in cardiac-allograft arteriosclerosis. N Engl J Med.1971;285:884–887.
81.
NabelEGPlautzGBoyceFM. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342–1344.
82.
ChoHJKimHSLeeMM. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation. 2003;108:2918–2925.
83.
WernerNJunkSLaufsU. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res.2003;93:e17–e24.
84.
HerringMGardnerAGloverJ. Seeding endothelium onto canine arterial prostheses. The effects of graft design. Arch Surg.1979;114:679–682.
85.
DichekDANevilleRFZwiebelJA. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation. 1989;80:1347–1353.
86.
BhattacharyaVMcSweeneyPAShiQ. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood. 2000;95:581–585.
87.
GrieseDPEhsanAMeloLG. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 2003;108:2710–2715.
88.
ShirotaTYasuiHMatsudaT. Intraluminal tissue-engineered therapeutic stent using endothelial progenitor cell-inoculated hybrid tissue and in vitro performance. Tissue Eng.2003;9:473–485.
89.
GrieseDPAchatzSBatzlspergerCA. Vascular gene delivery of anticoagulants by transplantation of retrovirally-transduced endothelial progenitor cells. Cardiovasc Res.2003;58:469–477.
